Life Sciences M&A

The life sciences M&A market continues to be reshaped by scientific breakthroughs, capital cycles, and intense competition for differentiated platforms.

These transactions are not simply financial events. They are strategic inflection points that define pipelines, platforms, and long-term value creation.

Goodwin Sits at the Center of This Market

We advise on some of the most significant and complex life sciences M&A transactions globally, representing companies, boards, and investors across the full lifecycle of strategic dealmaking.

These transactions reflect a clear market reality: strategic buyers competing for next-generation innovation, and companies increasingly using M&A as a core tool for value creation and liquidity.